Beranda › Leukemia-Limfoma Limfoblastik Sel T Prekursor
Uji klinis Leukemia-Limfoma Limfoblastik Sel T Prekursor yang merekrut di AS
23 studi untuk Leukemia-Limfoma Limfoblastik Sel T Prekursor merekrut peserta di lokasi di seluruh Amerika Serikat.
Kota dengan studi terbanyak
- Houston, TX8 studi
- New York City, NY6 studi
- Columbus, OH5 studi
- Washington, DC4 studi
- Philadelphia, PA4 studi
- Baldwin Park, CA3 studi
- St. Louis, MO3 studi
- Boston, MA3 studi
- Edison, NJ3 studi
- Queens, NY3 studi
- New Rochelle, NY3 studi
- Staten Island, NY3 studi
- East Norwalk, CT3 studi
Berdasarkan negara bagian
- California5 studi
- Colorado3 studi
- Florida3 studi
- Massachusetts3 studi
- Missouri3 studi
- New Jersey3 studi
- New York7 studi
- North Carolina3 studi
- Ohio6 studi
- Pennsylvania5 studi
- Tennessee3 studi
- Texas8 studi
Studi yang baru diperbarui
Teks studi resmi (Bahasa Inggris)
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Menerima pesertaFase 1
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06904066A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Menerima pesertaFase 2
6 Months · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06514794Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT04301076Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT01087333A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
Menerima pesertaFase 2
1 Month – 21 Years · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06561074Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Sep 2026 · NCT05289687Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma
Menerima pesertaFase 1
Hingga usia 39 · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT04972942Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma
Menerima pesertaFase 1
Usia 12 hingga 30 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT07513129Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Menerima pesertaFase 1
Hingga usia 75 · Semua jenis kelamin · Diperbarui 11 Agu 2026 · NCT03081910Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
Menerima pesertaFase 2
Usia 1 hingga 18 · Semua jenis kelamin · Diperbarui 10 Agu 2026 · NCT06390319Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Menerima pesertaFase 2
Semua usia · Semua jenis kelamin · Diperbarui 15 Jul 2026 · NCT00501826Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
Menerima pesertaFase 1
Usia 0 hingga 29 · Semua jenis kelamin · Diperbarui 7 Jul 2026 · NCT06934382Registry of Older Patients With Cancer
Menerima pesertaStudi observasional
Usia 65 ke atas · Semua jenis kelamin · Diperbarui 29 Jun 2026 · NCT01137825A Registry for People With T-cell Lymphoma
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 20 Mei 2026 · NCT05978141CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Menerima pesertaFase 1
Hingga usia 21 · Semua jenis kelamin · Diperbarui 19 Mei 2026 · NCT04318678Novel Unedited Allo Cell Therapy For High Risk T-Cell Malignancies Using CD7-Specific Car T Cells
Menerima pesertaFase 1
Hingga usia 75 · Semua jenis kelamin · Diperbarui 18 Mei 2026 · NCT07220993Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT07356245Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Apr 2026 · NCT05996185A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mar 2026 · NCT06698003Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 10 Feb 2026 · NCT04848064Two Step Haplo With Radiation Conditioning
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Okt 2025 · NCT05031897Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Menerima pesertaStudi observasional
Usia 18 hingga 120 · Semua jenis kelamin · Diperbarui 27 Okt 2025 · NCT01137643Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Apr 2025 · NCT06462365Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.